Intralesional BO-112 demonstrated promising clinical and pathological responses in patients with resectable basal cell ...
The National Eczema Association (NEA) has released the State of AD 2026 National Indicator Report, a Milliman analysis ...
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa. The second day of ...
Trispecific blockade of IL-4/IL-13 and upstream TSLP is intended to broaden type 2 inflammatory pathway coverage and potentially enhance durability versus single-axis inhibition. Week-16 EASI 75 rates ...
New data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress highlight the effects of ...
Nearly 95% of assessed TikTok “glass skin” videos contained potentially misleading claims, with none citing external references and none produced by dermatologists.
ILT7 is selectively expressed on plasmacytoid dendritic cells, and daxdilimab binding is intended to reduce pDCs in tissue ...
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
EPP arises from reduced ferrochelatase activity and excess protoporphyrin made largely in the bone marrow. Accurate diagnosis ...
Dr. Singh describes hedgehog pathway inhibitors as a frequent first-line option for patients with locally advanced basal cell carcinoma. Speaking as a Mohs surgeon, he nonetheless believes the class ...
Without a formal staging system, advanced basal cell carcinoma is defined by the interplay of tumor size, anatomic site, depth, histology, and host factors that may not be apparent on initial biopsy.
Nemolizumab (Nemluvio) maintained improvements in skin lesions, itch, sleep disturbance, and quality of life through 3 years in adults and adolescents with moderate to severe atop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results